Louis Navellier’s #1 Stock for 2022

On October 20, the man who recommended Google before anyone else will reveal his #1 stock pick for 2022 — for FREE — ticker symbol and all — in a special presentation.

Wed, October 20 at 4:00PM ET
 
 
 
 

7 Pharmaceutical Stocks to Buy Now

The grades of seven pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

NuPathe Inc.’s (PATH) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.

This week, GW Pharmaceuticals PLC Sponsored ADR (GWPH) pushes up from a C to a B rating. For more information, get Portfolio Grader’s complete analysis of GWPH stock.

Watson Pharmaceuticals (WPI) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

Paratek Pharmaceuticals Inc (PRTK) shows solid improvement this week. The company’s rating rises from a B to an A. In the past week, trade volume fell significantly to half the previous rate. For more information, get Portfolio Grader’s complete analysis of PRTK stock.

This week, Cardiome Pharma’s (CRME) ratings are up from a C last week to a B. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. For more information, get Portfolio Grader’s complete analysis of CRME stock.

This is a strong week for AbbVie, Inc. (ABBV). The company’s rating climbs to B from the previous week’s C. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. For more information, get Portfolio Grader’s complete analysis of ABBV stock.

ContraVir Pharmaceuticals, Inc. (CTRV) boosts its rating from a B to an A this week. For more information, get Portfolio Grader’s complete analysis of CTRV stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/07/7-pharmaceutical-stocks-to-buy-now-path-gwph-wpi-5/.

©2021 InvestorPlace Media, LLC